Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

NCT06588283 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Obesity

Interventions

DRUG: Ixekizumab
DRUG: Tirzepatide

Sponsor

Eli Lilly and Company